StockpollyBeta
ChatSearch/
Get AppSign in
Menu
Sign in
CategoryChatSearchMaster portfoliosResearch firmsBlog
Markets
Global MarketsHeatmapAI MapScreener
Tools
P/E CompareComparePortfolio
Company
AboutPricing
ContactFeedback
AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions
momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks
PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12
Delisting riskPopularity #4,858
CTOR · NASDAQ · Medical - Pharmaceuticals

Citius Oncology (CTOR)

CTOR

Commercializing LYMPHIR for relapsed or refractory cutaneous T-cell lymphoma.

$1.04
vs last close−0.04 (−3.27%)
OverviewEarningsFinancialsOwnershipNews

News type

  1. Citius Oncology (NASDAQ:CTOR) Stock Price Up 0.6% – Here’s What Happened

    Defense WorldJul 23

  2. Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® Commercialization

    PRNewsWireMay 5

  3. SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Citius Oncology, Inc. (NASDQ: CTOR)

    PRNewsWireJan 5

  4. Citius Oncology, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update

    PRNewsWireAug 12, 2025

  5. Citius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update

    PRNewsWireMay 14, 2025

  6. Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update

    PRNewsWireFeb 14, 2025

  7. Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services

    PRNewsWireFeb 6, 2025

  8. Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

    PRNewsWireDec 27, 2024

β 1.24briefsthe tapeclosesdividendstranscriptswiresliquidityclosesminutesYoY +18%threadsTSLAthreadsthreadsmarginsafter-hrstranscriptsmomentumVIX 14.2minutesrumorsupgradesQ3estimatesnewsflowbuybacksPCEthreadsvolatility13Fnarrativesflowsmomentumdowngradesyield curvesDXYdowngradessessions52w hiheadlinesyield curvesdowngradessentimentvolatilityyield curvesrumorsβ 1.24volumesfuturesforecaststickerspre-mktforecastschatterliquidityEPS 4.12newsflownoisedrawdownsGOOGLupgradesconsensuswires8-KliquidityconsensuswhispersMSFTheadlinespositioningbriefsthreadsEPS 4.12guidanceminutesnewsflow+0.8%cyclesestimates+2.41%marginsmarginsthreads2s10sliquiditycyclesnarrativesrumorsbuybacksvolumesPMI 52.1cycleschatter2s10stranscriptsconsensusmargins
GDPclosesYoY +18%buybacksnewsflow13FrevisionsflowsT+1positioningrevisionsnewsflowconsensusvolumesfilingsAAPLfuturesYoY +18%futuresmarginsflowsvolatilityrevisionsDXYwhispersearnings callspositioningAVGOcatalystsyield curvesMETA10-Kconsensus
P/E 28.4catalystsspx 0dtecatalystsbid/askvolatilityheadlinesguidancedrawdowns
Stockpolly
An agent-based financial analysis engine for public markets.
© 2026 Stockpolly. All rights reserved.
Company
AboutPricing
Legal
TermsPrivacy
Support
ContactFeedback